Inmazeb
These highlights do not include all the information needed to use INMAZEB safely and effectively. See full prescribing information for INMAZEB. INMAZEB (atoltivimab, maftivimab, and odesivimab-ebgn) injection, for intravenous use Initial U.S. Approval: 2020
0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa
HUMAN PRESCRIPTION DRUG LABEL
Dec 20, 2022
Regeneron Pharmaceuticals, Inc.
DUNS: 194873139
Products 2
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
atoltivimab, maftivimab, and odesivimab-ebgn
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (8)
atoltivimab, maftivimab, and odesivimab-ebgn
Product Details
FDA regulatory identification and product classification information